SHPG up +0.87% percent Today $SHPG High is at 202.40 and the Low 201.60 with current volume of 220,678.
Recent News posted below.
Shire Plc American Depositary Shares SHPG other info.
http://investorshangout.com/Shire-Plc-SHPG-55423/
SHPG Shire Plc American Depositary Shares Recent Headline News
Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 4 mins ago
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 49.78 (+0.05), SHPG: 202.52 (+2.01), SCMP: 11.37 (+0.95), CEMP: 14.64 (+0.47)
Research and Markets: North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
Business Wire - Thu Nov 13, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bx55x/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering.
SNN: 33.61 (+0.08), SHPG: 202.52 (+2.01)
North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
M2 - Thu Nov 13, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vj74f/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the North America Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Scope - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the North America Tissue Engineered - Skin Substitutes. Companies Mentioned - Organogenesis, Inc. - Shire Plc - Kinetic Concepts, Inc. - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - Molnlycke Health Care AB - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/8v...th_america
SNN: 33.61 (+0.08), IART: 48.32 (+0.09), SHPG: 202.52 (+2.01)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 202.52 (+2.01), PFE: 30.57 (+0.15), AZN: 74.65 (+0.39), ABBV: 64.09 (+0.33), WAG: 67.09 (-0.35)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 4.20 (+0.16), SHPG: 202.52 (+2.01)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 318.91 (-2.11), GILD: 103.70 (-3.20), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33), CELG: 107.63 (-0.62)
The Zacks Analyst Blog Highlights: UBS, Shire and Mallinckrodt
PR Newswire - Mon Nov 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the UBS AG (NYSE:UBS-Free Report), Shire plc (Nasdaq:SHPG-Free Report) and Mallinckrodt plc (NYSE:MNK-Free Report).
SHPG: 202.52 (+2.01)
ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 87.43 (-5.56), SHPG: 202.52 (+2.01), UBS: 17.55 (+0.17)
The Zacks Analyst Blog Highlights: AbbVie, Shire, Medtronic, Unilife and Derma Sciences
PR Newswire - Fri Nov 07, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report), Unilife Corporation (Nasdaq:UNIS-Free Report) and Derma Sciences Inc. (Nasdaq
SCI-Free Report).
DSCI: 8.61 (+0.02), UNIS: 3.02 (-0.02), MDT: 69.38 (+0.88), SHPG: 202.52 (+2.01)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 64.85 (+0.01), JNJ: 109.00 (+0.25), PCYC: 140.07 (+2.70), SHPG: 202.52 (+2.01), MRK: 59.74 (+0.43), AMGN: 160.76 (-1.17)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 202.52 (+2.01), PFE: 30.57 (+0.15), MRK: 59.74 (+0.43), AZN: 74.65 (+0.39), TEVA: 57.79 (-0.65), ITCI: 15.06 (-0.14), ABBV: 64.09 (+0.33), BMY: 57.98 (-0.63), OMER: 19.07 (-0.64)
Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 8.61 (+0.02), MDT: 69.38 (+0.88), UNIS: 3.02 (-0.02), COV: 93.81 (+0.93), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33), WAG: 67.09 (-0.35)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.95 (+0.44), VRX: 133.24 (+2.15), ACT: 242.63 (+2.01), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33)
Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference
PR Newswire - Thu Nov 06, 6:00AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at the Arizona Biltmore Hotel in Phoenix, Arizona. Flemming Ornskov, MD, Chief Executive Officer will present at 3:30 PM Mountain Standard Time (5:30 PM EST; 10:30 PM UK time).
SHPG: 202.52 (+2.01)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.73 (+1.40), ENDP: 67.79 (-0.10), AUXL: 32.53 (+0.01), SHPG: 202.52 (+2.01), DNDN: 0.15 (-0.01), SNSS: 1.63 (-0.05), ABBV: 64.09 (+0.33), SNY: 46.74 (+0.18), MNKD: 6.24 (+0.16), XOMA: 4.03 (-0.05)
Critical Alerts For Apple, LightInTheBox, Time, 21st Century Fox and Shire Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, LITB, TIME, FOXA and SHPG.
TIME: 22.07 (-0.19), SHPG: 202.52 (+2.01), FOXA: 34.82 (+0.18), AAPL: 112.89 (+1.64), LITB: 8.06 (+0.03)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 59.74 (+0.43), SHPG: 202.52 (+2.01)
Why AbbVie Inc. Stock Vaulted Higher By 11% in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 12:51PM CST
ABBV data by YCharts What: Pharmaceutical juggernaut AbbVie found its wings in October and leaped higher by 11%, according to data from S&P Capital IQ , following better than expected third-quarter earnings and the termination of a...
SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.32 (-0.01), SHPG: 202.52 (+2.01), MRK: 59.74 (+0.43), PFE: 30.57 (+0.15), SNY: 46.74 (+0.18)
Recent News posted below.
Shire Plc American Depositary Shares SHPG other info.
http://investorshangout.com/Shire-Plc-SHPG-55423/
SHPG Shire Plc American Depositary Shares Recent Headline News
Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 4 mins ago
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 49.78 (+0.05), SHPG: 202.52 (+2.01), SCMP: 11.37 (+0.95), CEMP: 14.64 (+0.47)
Research and Markets: North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
Business Wire - Thu Nov 13, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bx55x/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering.
SNN: 33.61 (+0.08), SHPG: 202.52 (+2.01)
North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
M2 - Thu Nov 13, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vj74f/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the North America Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Scope - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the North America Tissue Engineered - Skin Substitutes. Companies Mentioned - Organogenesis, Inc. - Shire Plc - Kinetic Concepts, Inc. - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - Molnlycke Health Care AB - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/8v...th_america
SNN: 33.61 (+0.08), IART: 48.32 (+0.09), SHPG: 202.52 (+2.01)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 202.52 (+2.01), PFE: 30.57 (+0.15), AZN: 74.65 (+0.39), ABBV: 64.09 (+0.33), WAG: 67.09 (-0.35)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 4.20 (+0.16), SHPG: 202.52 (+2.01)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 318.91 (-2.11), GILD: 103.70 (-3.20), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33), CELG: 107.63 (-0.62)
The Zacks Analyst Blog Highlights: UBS, Shire and Mallinckrodt
PR Newswire - Mon Nov 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the UBS AG (NYSE:UBS-Free Report), Shire plc (Nasdaq:SHPG-Free Report) and Mallinckrodt plc (NYSE:MNK-Free Report).
SHPG: 202.52 (+2.01)
ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 87.43 (-5.56), SHPG: 202.52 (+2.01), UBS: 17.55 (+0.17)
The Zacks Analyst Blog Highlights: AbbVie, Shire, Medtronic, Unilife and Derma Sciences
PR Newswire - Fri Nov 07, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report), Unilife Corporation (Nasdaq:UNIS-Free Report) and Derma Sciences Inc. (Nasdaq
SCI-Free Report). DSCI: 8.61 (+0.02), UNIS: 3.02 (-0.02), MDT: 69.38 (+0.88), SHPG: 202.52 (+2.01)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 64.85 (+0.01), JNJ: 109.00 (+0.25), PCYC: 140.07 (+2.70), SHPG: 202.52 (+2.01), MRK: 59.74 (+0.43), AMGN: 160.76 (-1.17)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 202.52 (+2.01), PFE: 30.57 (+0.15), MRK: 59.74 (+0.43), AZN: 74.65 (+0.39), TEVA: 57.79 (-0.65), ITCI: 15.06 (-0.14), ABBV: 64.09 (+0.33), BMY: 57.98 (-0.63), OMER: 19.07 (-0.64)
Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 8.61 (+0.02), MDT: 69.38 (+0.88), UNIS: 3.02 (-0.02), COV: 93.81 (+0.93), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33), WAG: 67.09 (-0.35)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.95 (+0.44), VRX: 133.24 (+2.15), ACT: 242.63 (+2.01), SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33)
Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference
PR Newswire - Thu Nov 06, 6:00AM CST
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at the Arizona Biltmore Hotel in Phoenix, Arizona. Flemming Ornskov, MD, Chief Executive Officer will present at 3:30 PM Mountain Standard Time (5:30 PM EST; 10:30 PM UK time).
SHPG: 202.52 (+2.01)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.73 (+1.40), ENDP: 67.79 (-0.10), AUXL: 32.53 (+0.01), SHPG: 202.52 (+2.01), DNDN: 0.15 (-0.01), SNSS: 1.63 (-0.05), ABBV: 64.09 (+0.33), SNY: 46.74 (+0.18), MNKD: 6.24 (+0.16), XOMA: 4.03 (-0.05)
Critical Alerts For Apple, LightInTheBox, Time, 21st Century Fox and Shire Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, LITB, TIME, FOXA and SHPG.
TIME: 22.07 (-0.19), SHPG: 202.52 (+2.01), FOXA: 34.82 (+0.18), AAPL: 112.89 (+1.64), LITB: 8.06 (+0.03)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 59.74 (+0.43), SHPG: 202.52 (+2.01)
Why AbbVie Inc. Stock Vaulted Higher By 11% in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 12:51PM CST
ABBV data by YCharts What: Pharmaceutical juggernaut AbbVie found its wings in October and leaped higher by 11%, according to data from S&P Capital IQ , following better than expected third-quarter earnings and the termination of a...
SHPG: 202.52 (+2.01), ABBV: 64.09 (+0.33)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.32 (-0.01), SHPG: 202.52 (+2.01), MRK: 59.74 (+0.43), PFE: 30.57 (+0.15), SNY: 46.74 (+0.18)
